• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Transactions of the Royal Society of Tropical Medicine and Hygiene >The treatment of visceral leishmaniasis (kala-azar) in India: No obvious signs of long-term success
【24h】

The treatment of visceral leishmaniasis (kala-azar) in India: No obvious signs of long-term success

机译：印度内脏利什曼病（黑热病）的治疗：没有长期成功的明显迹象

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

In India, the eastern state of Bihar is particularly badly affected by visceral leishmaniasis (VL). It was in Bihar in the 1980s that the first clear signs of resistance to pentavalent antimonials, which had then been the standard antileishmanial treatment for several decades, were observed. New drugs and new formulations of old drugs have since been developed for the treatment of VL. However, despite some initial signs of benefit after each major revision in the method of treatment of VL in India, the VL-related case fatality rates recorded in India since the 1970s show no clear evidence of long-term success. In fact, the most recent data indicate that such rates have stabilised or even increased, probably because of the continued usage of sodium stibogluconate in northern Bihar.
机译：在印度，东部比哈尔邦受内脏利什曼病（VL）的影响特别严重。在1980年代的比哈尔邦，观察到了对五价锑抗药性的第一个明显迹象，这种抗药性几十年来一直是标准的抗疟药处理。此后，已经开发出用于治疗VL的新药和旧药的新配方。但是，尽管在印度对VL的治疗方法进行每次重大修订后都有一些最初的获益迹象，但自1970年代以来在印度记录的与VL相关的病例死亡率未显示长期成功的明确证据。实际上，最新数据表明，此类比率已经稳定，甚至有所增加，这可能是因为在比哈尔邦北部继续使用司考葡糖酸钠。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号